The trial that has the most potential to add immediate value is...

The trial that has the most potential to add immediate value is the HER2 negative breast cancer Phase I-II Study of PTX-200. This trial is being conducted at the Moffitt Cancer Center in Florida, USA. These guys are reputable therefore a leak of any kind is highly unlikely as has been speculated.

"A range of AKT inhibitors is in clinical development for various oncology indications. While most compounds bind to the ATP site of AKT, ARQ-092 (ArQule, Burlington, MA, USA), MK-2206 (Merck Co., Kenilworth, NJ, USA), and ipatasertib (Roche, Basel, Switzerland) are allosteric inhibitors of AKT. ARQ-751 (ArQule) is in Phase I clinical development. ARQ-92, MK2206, ipatasertib as well as capivasertib (Astra Zeneca), uprosertib (GSK, Brentford, UK), and triciribine (Prescient Therapeutics, South Melbourne, Australia) have made it into Phase II trials in oncology indications (Figure 2). ARQ-092 is tested in patients with PROS and Proteus Syndrome (NCT03094832)."



It's worth noting the very small number of companies that have Phase II trials in this unique space.

Prescient Therapeutics Limited - $32m MC

- Phase I-II Study of PTX-200 (Triciribine) Breast Cancer
https://ichgcp.net/clinical-trials-registry/NCT01697293


Astra Zeneca - $125b (US)

- Phase II trial of AKT inhibitor MK-2206 (failed) Breast Cancer
https://www.ncbi.nlm.nih.gov/pubmed/31277699

- Phase 1/2 study of oral ARQ 092 (Miransertib) Proteus Syndrome
https://www.childrenshospital.org/clinical-trials/nct03094832

GSK - $110b (US)

-Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma
https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.9068

The other companies MC's mean little as they are obviously not solely focused on these trials but it gives some idea about just how few have programs in this space and just how big the budgets of those likely to buy it out in the success case are. There's a good article for those more technically minded linked below.

https://www.mdpi.com/1422-0067/20/22/5792/htm

By the way the primary completion date listed for our phase 1/2 trial is 01-12-2019 so about a week away.